181 related articles for article (PubMed ID: 16930497)
21. Botulinum neurotoxin A for benign prostatic hyperplasia.
Oeconomou A; Madersbacher H
Curr Opin Urol; 2010 Jan; 20(1):28-36. PubMed ID: 19887944
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic effects of add-on botulinum toxin A on patients with large benign prostatic hyperplasia and unsatisfactory response to combined medical therapy.
Kuo HC; Liu HT
Scand J Urol Nephrol; 2009; 43(3):206-11. PubMed ID: 19308807
[TBL] [Abstract][Full Text] [Related]
23. Is botulinum neurotoxin type A (BoNT-A) a novel therapy for lower urinary tract symptoms due to benign prostatic enlargement? A review of the literature.
Oeconomou A; Madersbacher H; Kiss G; Berger TJ; Melekos M; Rehder P
Eur Urol; 2008 Oct; 54(4):765-75. PubMed ID: 18571306
[TBL] [Abstract][Full Text] [Related]
24. [Botulinum toxin type-A toxin activity on prostate cancer cell lines].
Proietti S; Nardicchi V; Porena M; Giannantoni A
Urologia; 2012; 79(2):135-41. PubMed ID: 22610840
[TBL] [Abstract][Full Text] [Related]
25. Intraprostatic botulinum neurotoxin type a injection for benign prostatic hyperplasia: preliminary results with a newly purified neurotoxin.
Yokoyama T; Yamamoto Y; Suzuki T; Oguma K; Nagai A
Acta Med Okayama; 2012; 66(4):291-7. PubMed ID: 22918201
[TBL] [Abstract][Full Text] [Related]
26. Botulinum toxin for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia.
Antunes AA; Srougi M; Coelho RF; de Campos Freire G
Nat Clin Pract Urol; 2007 Mar; 4(3):155-60. PubMed ID: 17347660
[TBL] [Abstract][Full Text] [Related]
27. Botulinum Toxin A and Lower Urinary Tract Dysfunction: Pathophysiology and Mechanisms of Action.
Jhang JF; Kuo HC
Toxins (Basel); 2016 Apr; 8(4):120. PubMed ID: 27110822
[TBL] [Abstract][Full Text] [Related]
28. Botulinum toxin A injection to the bladder neck and urethra for medically refractory lower urinary tract symptoms in men without prostatic obstruction.
Chen JL; Chen CY; Kuo HC
J Formos Med Assoc; 2009 Dec; 108(12):950-6. PubMed ID: 20040460
[TBL] [Abstract][Full Text] [Related]
29. Lysozyme gene treatment in testosterone induced benign prostate hyperplasia rat model and comparasion of its' effectiveness with botulinum toxin injection.
Ergün O; Koşar PA; Onaran İ; Darici H; Koşar A
Int Braz J Urol; 2017; 43(6):1167-1175. PubMed ID: 28727388
[TBL] [Abstract][Full Text] [Related]
30. Management of bladder, prostatic and pelvic floor disorders with botulinum neurotoxin.
Maria G; Cadeddu F; Brisinda D; Brandara F; Brisinda G
Curr Med Chem; 2005; 12(3):247-65. PubMed ID: 15723617
[TBL] [Abstract][Full Text] [Related]
31. [Intraprostatic injection therapy in patients with benign prostatic syndrome].
Bschleipfer T; Bach T; Gratzke C; Madersbacher S; Oelke M
Urologe A; 2013 Mar; 52(3):354-8. PubMed ID: 23435646
[TBL] [Abstract][Full Text] [Related]
32. A multicenter, randomized, double-blind, placebo controlled study of onabotulinumtoxinA 200 U to treat lower urinary tract symptoms in men with benign prostatic hyperplasia.
McVary KT; Roehrborn CG; Chartier-Kastler E; Efros M; Bugarin D; Chen R; Patel A; Haag-Molkenteller C
J Urol; 2014 Jul; 192(1):150-6. PubMed ID: 24508634
[TBL] [Abstract][Full Text] [Related]
33. Meta-analysis of botulinum toxin in the treatment of benign prostatic hyperplasia.
Jing C; Chen L; Huang X
Minerva Surg; 2024 Feb; 79(1):117-119. PubMed ID: 35023701
[No Abstract] [Full Text] [Related]
34. Application of Botulinum Neurotoxin in Male Sexual Dysfunction: Where Are We Now?
Reddy AG; Dick BP; Natale C; Akula KP; Yousif A; Hellstrom WJG
Sex Med Rev; 2021 Apr; 9(2):320-330. PubMed ID: 32641225
[TBL] [Abstract][Full Text] [Related]
35. Current and potential urological applications of botulinum toxin A.
Jiang YH; Liao CH; Kuo HC
Nat Rev Urol; 2015 Sep; 12(9):519-33. PubMed ID: 26260879
[TBL] [Abstract][Full Text] [Related]
36. Botulinum toxin type A: Exploring new indications.
Brashear A
Drugs Today (Barc); 2010 Sep; 46(9):671-82. PubMed ID: 20967299
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of botulinum toxin injection for benign prostatic hyperplasia: a systematic review and meta-analysis.
Shim SR; Cho YJ; Shin IS; Kim JH
Int Urol Nephrol; 2016 Jan; 48(1):19-30. PubMed ID: 26560471
[TBL] [Abstract][Full Text] [Related]
38. [Pittsburgh experience with botulinum toxin A injection].
de Miguel F; Chancellor MB
Actas Urol Esp; 2006 Mar; 30(3):310-4. PubMed ID: 16749589
[TBL] [Abstract][Full Text] [Related]
39. Emerging Minimally Invasive Treatment Options for Male Lower Urinary Tract Symptoms.
Magistro G; Chapple CR; Elhilali M; Gilling P; McVary KT; Roehrborn CG; Stief CG; Woo HH; Gratzke C
Eur Urol; 2017 Dec; 72(6):986-997. PubMed ID: 28734706
[TBL] [Abstract][Full Text] [Related]
40. Intraprostatic botulinum toxin type "A" injection in patients with benign prostatic hyperplasia and unsatisfactory response to medical therapy: A randomized, double-blind, controlled trial using urodynamic evaluation.
Totaro A; Pinto F; Pugliese D; Vittori M; Racioppi M; Foschi N; Bassi PF; Sacco E
Neurourol Urodyn; 2018 Mar; 37(3):1031-1038. PubMed ID: 28840969
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
